Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC.
説明 | Belizatinib (TSR-011) is an effective, oral and dual inhibitor of ALK (IC50: 0.7 nM, wild-type recombinant ALK) and TRKA, TRKB, and TRKC. |
ターゲット&IC50 | ALK:0.7 nM |
In vitro | In the Clinicalal trials, Belizatinib has antitumor activity. |
In vivo | In mouse models, Belizatinib can continuously and effectively inhibit ALK-dependent tumor growth. |
別名 | TSR-011 |
分子量 | 577.73 |
分子式 | C33H44FN5O3 |
CAS No. | 1357920-84-3 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 300 mg/mL
You can also refer to dose conversion for different animals. 詳細
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Belizatinib 1357920-84-3 Angiogenesis Tyrosine Kinase/Adaptors Trk receptor ALK Trk Receptor CD246 ALK tyrosine kinase receptor TSR011 Tropomyosin related kinase receptor TSR 011 inhibit Cluster of differentiation 246 TSR-011 Inhibitor Anaplastic lymphoma kinase Anaplastic lymphoma kinase (ALK) inhibitor